Ronald Carter, MD appointed as Chief Medical Officer Tim Sharpington appointed as Chief Operating Officer Cambridge, UK, 04 February 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces the appointment of Ronald Carter, MD, as Chief Medical Officer (CMO), and the appointment of Tim Sharpington as Chief Operating Officer (COO). Ron […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2021-02-04 11:53:022021-05-05 11:04:06Microbiotica Expands Management Team with Appointments of Chief Medical Officer and Chief Operating Officer
Cambridge, UK, 18 September 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the Year” category is awarded to the most exciting recently incorporated enterprise in any sector that has made significant progress in the last 12 months. […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-09-18 17:11:172020-09-18 17:11:17Microbiotica Wins Young Company of the Year at Business Weekly Awards
Cambridge, UK, 9 September 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-09-09 16:13:082021-05-05 11:04:41Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
Cambridge, UK, 13 August 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today congratulates Co-founder Gordon Dougan, FRS, Professor in the Department of Medicine and the Cambridge Institute for Therapeutic Immunology and Infectious Disease at the University of Cambridge, on being awarded the 2020 Albert B. Sabin Gold Medal. The Gold Medal, […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-08-13 15:07:482020-08-13 15:44:16Microbiotica Co-founder Professor Gordon Dougan Receives 2020 Albert B. Sabin Gold Medal
Collaboration in immuno-oncology microbiome therapeutic and biomarker development Partnership based on class-leading MELRESIST melanoma study and new MITRE landmark study in 1,800 patients in multiple cancers Uses Microbiotica’s unrivalled microbiome platform Cambridge, UK, 8 June 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-06-09 14:05:282020-06-17 15:02:50Microbiotica, Cancer Research UK and Cambridge University Hospitals collaborate in landmark cancer microbiome study
Cambridge, UK, 14 May 2020 – It was with great sadness that the Board of Microbiotica learned of the death of its Chairman, Thomas Lynch, who passed away on 1st April 2020. Thomas had been Chairman of Microbiotica since September 2019 and brought a wealth of experience and guidance to the Board. Thomas had a highly […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-05-14 09:00:552020-05-26 14:15:45Microbiotica Statement About Chairman Thomas Lynch
Cambridge, UK, 9 January 2020 – Microbiotica, a leading player in microbiome-based therapeutics, confirms its upcoming investor and scientific conference attendance during Q1 2020. Biotech Showcase 2020, 13-15 January 2020, San Francisco, US Held during the week of the JPM Healthcare Conference in San Francisco, the conference provides private and public biotechnology and life sciences companies […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2020-01-09 09:00:312020-05-26 14:22:18Microbiotica to Attend Key Industry Conferences in Q1 2020
Cambridge, UK, 19 November 2019: Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is relocating to the Park in a two-phase move that will be completed in June 2020. Microbiotica’s continuing development and expansion, and the ability of Chesterford Research Park to flexibly accommodate both Microbiotica’s immediate […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2019-11-19 09:00:192020-05-26 14:53:51Microbiotica relocates to Chesterford Research Park, Cambridge
Cambridge, UK, 25 September 2019 – Microbiotica, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019. Thomas Lynch brings extensive life sciences and wider board-level experience which will be invaluable in supporting Microbiotica’s strategic growth. He currently holds a number of board positions on private and […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2019-09-25 09:00:372020-06-11 11:06:21Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman
Cambridge, UK, 18 September 2019 – Microbiotica, a leading player in microbiome-based live therapeutics, has been selected as a finalist in the ‘Best Partnership Alliance’ category at the Scrip Awards 2019. The winners will be announced on 4 December 2019. Microbiotica has been recognised for its multi-year strategic collaboration with Genentech, which was announced in […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2019-09-18 09:00:562020-05-26 14:54:01Microbiotica announced as a finalist in ‘Best Partnership Alliance’ category at Scrip Awards 2019
Find us on LinkedIn
info@microbiotica.com
Microbiotica Expands Management Team with Appointments of Chief Medical Officer and Chief Operating Officer
/in News /by immunocityRonald Carter, MD appointed as Chief Medical Officer Tim Sharpington appointed as Chief Operating Officer Cambridge, UK, 04 February 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces the appointment of Ronald Carter, MD, as Chief Medical Officer (CMO), and the appointment of Tim Sharpington as Chief Operating Officer (COO). Ron […]
Microbiotica Wins Young Company of the Year at Business Weekly Awards
/in News /by immunocityCambridge, UK, 18 September 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the Year” category is awarded to the most exciting recently incorporated enterprise in any sector that has made significant progress in the last 12 months. […]
Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
/in News /by immunocityCambridge, UK, 9 September 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most […]
Microbiotica Co-founder Professor Gordon Dougan Receives 2020 Albert B. Sabin Gold Medal
/in News /by immunocityCambridge, UK, 13 August 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today congratulates Co-founder Gordon Dougan, FRS, Professor in the Department of Medicine and the Cambridge Institute for Therapeutic Immunology and Infectious Disease at the University of Cambridge, on being awarded the 2020 Albert B. Sabin Gold Medal. The Gold Medal, […]
Microbiotica, Cancer Research UK and Cambridge University Hospitals collaborate in landmark cancer microbiome study
/in News /by immunocityCollaboration in immuno-oncology microbiome therapeutic and biomarker development Partnership based on class-leading MELRESIST melanoma study and new MITRE landmark study in 1,800 patients in multiple cancers Uses Microbiotica’s unrivalled microbiome platform Cambridge, UK, 8 June 2020 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation […]
Microbiotica Statement About Chairman Thomas Lynch
/in News /by immunocityCambridge, UK, 14 May 2020 – It was with great sadness that the Board of Microbiotica learned of the death of its Chairman, Thomas Lynch, who passed away on 1st April 2020. Thomas had been Chairman of Microbiotica since September 2019 and brought a wealth of experience and guidance to the Board. Thomas had a highly […]
Microbiotica to Attend Key Industry Conferences in Q1 2020
/in News /by immunocityCambridge, UK, 9 January 2020 – Microbiotica, a leading player in microbiome-based therapeutics, confirms its upcoming investor and scientific conference attendance during Q1 2020. Biotech Showcase 2020, 13-15 January 2020, San Francisco, US Held during the week of the JPM Healthcare Conference in San Francisco, the conference provides private and public biotechnology and life sciences companies […]
Microbiotica relocates to Chesterford Research Park, Cambridge
/in News /by immunocityCambridge, UK, 19 November 2019: Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is relocating to the Park in a two-phase move that will be completed in June 2020. Microbiotica’s continuing development and expansion, and the ability of Chesterford Research Park to flexibly accommodate both Microbiotica’s immediate […]
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman
/in News /by immunocityCambridge, UK, 25 September 2019 – Microbiotica, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019. Thomas Lynch brings extensive life sciences and wider board-level experience which will be invaluable in supporting Microbiotica’s strategic growth. He currently holds a number of board positions on private and […]
Microbiotica announced as a finalist in ‘Best Partnership Alliance’ category at Scrip Awards 2019
/in News /by immunocityCambridge, UK, 18 September 2019 – Microbiotica, a leading player in microbiome-based live therapeutics, has been selected as a finalist in the ‘Best Partnership Alliance’ category at the Scrip Awards 2019. The winners will be announced on 4 December 2019. Microbiotica has been recognised for its multi-year strategic collaboration with Genentech, which was announced in […]